natgillin/translations-raw huggingface dataset:
Det primære effektmål var antallet af patienter, der opnåede en forlængelse af "on"-perioden på mindst en time i løbet af tre uger efter lægemiddelskiftet.
The main measure of effectiveness was the number of patients with an increase in ‘on’ time of one hour or more, during the three weeks following the switch.
Det primære effektmål var antallet af patienter, der responderede på behandlingen, på grundlag af antallet og sværhedsgraden af symptomer.
The main measure of effectiveness was the number of patients who responded to treatment, based on the number and severity of symptoms.
Det primære effektmål var antallet af patienter, hos hvem der ikke var nogen »påviselig« virusbelastning (under 50 kopier/ml blod) efter 48 uger.
The main measure of effectiveness was the number of patients who had ‘undetectable’ viral loads (below 50 copies per millilitre of blood) after 48 weeks;
Det primære effektmål var antallet af patienter, hos hvilke der kunne indsamles et målantal stamceller fra blodet inden for to eller fire indsamlingsdage.
The main measure of effectiveness was the number of patients in whom a target number of stem cells could be collected from the blood within two or four collection days.
Det primære effektmål var antallet af patienter, hvis invaliditet forværredes.
The main measure of effectiveness was the number of patients whose disability got worse.
Det primære effektmål var antallet af patienter, som havde en "komplet respons", defineret som en reduktion i blodpladetallet på mindst 50 % fra behandlingsstart eller ned til under 600 mio./ml.
The main measure of effectiveness was the number of patients who had a ‘complete response’, defined as a reduction in platelet counts of at least 50% from the start of treatment or to below 600 million/ml.
Det primære effektmål var antallet af patienter, som havde et fald i kalciumindholdet i blodet på mere end 1 mg pr. deciliter på det tidspunkt, hvor der var fundet en vedligeholdelsesdosis (mellem to og 16 uger efter undersøgelsens start).
The main measure of effectiveness was the number of patients who had a reduction in blood calcium levels of more than 1 mg per decilitre by the time a maintenance dose had been found (between two and 16 weeks after the start of the study).
Det primære effektmål var antallet af patienter, som ikke havde påviseligt virus i blodet 24 uger efter afslutningen af behandlingen, og som derfor kunne anses for at være helbredt.
The main measure of effectiveness was the number of patients who had no detectable virus in their blood 24 weeks after the end of the treatment and could therefore be considered to be cured.
Det primære effektmål var antallet af patienter, som responderede på Revolade (hos hvem antallet af blodplader, røde blodceller eller hvide blodceller forblev over de forud fastsatte niveauer) efter 12 eller 16 ugers behandling.
The main measure of effectiveness was the number of patients who responded to Revolade (whose platelet, red or white blood cell count remained above pre-set levels) after 12 or 16 weeks of treatment.
Det primære effektmål var antallet af voksne, som blev testet positive for hiv-1-infektion.
The main measure of effectiveness was the number of adults who tested positive for HIV-1 infection.
Det primære effektmål var antistofniveauet i blodet mod viraene i vaccinen med undtagelse af FeLV-komponenten, hvis effektivitet med hensyn til beskyttelse mod infektion allerede var påvist i andre undersøgelser.
The main measure of effectiveness was the level of antibodies in the blood against the viruses in the vaccine, with the exception of the FeLV component, whose effectiveness in preventing infection had already been demonstrated in other studies.
Det primære effektmål var antistofniveauet i blodet mod viraene og bakterierne i vaccinen med undtagelse af FeLV-komponenten, hvis effektivitet med hensyn til beskyttelse mod infektion allerede var vist i andre undersøgelser.
The main measure of effectiveness was the level of antibodies in the blood against the viruses and bacteria in the vaccine, with the exception of the FeLV component, whose effectiveness in preventing infection had already been demonstrated in other studies.
Det primære effektmål var baseret på, hvor mange patienter der fik et nyt hjerteanfald, et slagtilfælde eller der døde af en hjerte- kar-sygdom.
The main measure of effectiveness was based on the number of patients having another heart attack, a stroke or dying from a cardiovascular disease.
Det primære effektmål var den andel af patienterne, som opnåede en PGA-score på clear (0) eller minimal (1) i uge 12.
The primary endpoint was the proportion of patients who achieve a PGA score of cleared (0) or minimal (1) at week 12.
Det primære effektmål var den gennemsnitlige ændring i forhold til baseline af samlet vurderingsskala for Parkinsons sygdom (UPDRS) del II- (dagligdags aktiviteter) scorer plus del III-motorscore i uge 30 eller ved førtidigt ophør.
The primary efficacy endpoint was the mean change from baseline of the Unified Parkinson’s Disease Rating Scale (UPDRS) Part II (activities of daily living) score plus Part III motor score at week 30 or early termination.
Det primære effektmål var den tid, patienterne var i "off-tilstand" i løbet af dagen, således som registreret i patientdagbøgerne.
The main measure of effectiveness was the time spent in the ‘off’ state during the day, as recorded in patients’ diaries.
Det primære effektmål var en reduktion af kolesterolniveauet efter 12 uger (undtagen HDL eller "godt" kolesterol).
The main measure of effectiveness was the reduction in the level of cholesterol after 12 weeks (excluding HDL or ‘good’ cholesterol).
Det primære effektmål var faldet i LDL- kolesteroltallet efter fire til seks uger, bortset fra en af undersøgelserne, hvor man så nærmere på Cholestagel taget alene, og hvor man målte kolesteroltallet efter seks måneder.
The main measure of effectiveness was the decrease in LDL-cholesterol levels after four to six weeks, except for one of the studies looking at Cholestagel taken on its own, which measured the cholesterol levels after six months.
Det primære effektmål var fedtabsorptionskoefficienten over
The primary efficacy endpoint was the coefficient of fat absorption over
Det primære effektmål var forbedringen i den afstand, patienterne kunne gå på seks minutter, og forbedringen i deres ”forcerede vitalkapacitet” (et mål for, hvor godt deres lunger fungerede).
The main measures of effectiveness were the improvement in the distance the patients could walk in six minutes and in their ‘forced vital capacity’ (a measure of how well their lungs were working).
Det primære effektmål var forskellen i smerternes intensitet i en periode på 30 minutter efter behandlingen.
The main measure of effectiveness was the change in the severity of their pain during the 30 minutes after treatment.
Det primære effektmål var lungefunktionen ("forceret vitalkapacitet", som er den maksimale mængde luft, patienten kunne udånde) og den distance, patienterne kunne gå på seks minutter, hvilket måler sygdommens kombinerede indvirkning på hjerte, lunger, led og andre organer.
The main measures of effectiveness were lung function (‘forced vital capacity’, the maximum amount of air the patient could breathe out), and the distance the patients could walk in six minutes, which measures the combined effects of the illness on the heart, lungs, joints and other organs.
Det primære effektmål var lægens vurdering af, hvor godt blødningen var standset.
The main measure of effectiveness was the doctor’s assessment of how well bleeding was stopped.
Det primære effektmål var mindskelsen af symptomerne på artritis efter behandlingen, patienternes fysiske funktion (evnen til at udføre daglige aktiviteter) og omfanget af ledskader (vurderet på røntgenbilleder).
The main measures of effectiveness were the reduction in symptoms of arthritis after treatment, as well as physical function (the ability to carry out everyday tasks) and the amount of damage to the joints (assessed using X-rays).
Det primære effektmål var opnåelse af fuldstændig remission ved måned 6, defineret som en BVAS/WG-score (Birmingham Vasculitis Activity Score for Wegener’s Granulomatosis) på 0 og ophørt glukokortikoidbehandling.
The primary outcome measure was achievement of complete remission at 6 months defined as a Birmingham Vasculitis Activity Score for Wegener’s granulomatosis (BVAS/WG) of 0, and off glucocorticoid therapy.
Det primære effektmål var produktionen af beskyttende niveauer af antistoffer over for C. perfringens i kyllingernes blod og i deres æg.
The main measure of effectiveness was the production of protective antibodies against C. perfringens type A in the chickens’ blood and in their eggs.
Det primære effektmål var responsrate defineret som den procentdel, der udviste en forbedring på ≥ 3 point på mTDS-skalaen (modified Teacher's Drooling Scale).
Primary efficacy endpoint was responder rate, defined as percentage showing ≥3-point improvement on the modified Teacher’s Drooling Scale (mTDS).
Det primære effektmål var samlet overlevelse (hvor længe patienterne levede i gennemsnit).
The main measure of effectiveness was overall survival (the average length of time the patients lived).
Det primære effektmål var samlet overlevelse.
The primary endpoint was overall survival.
Det primære effektmål var smerteintensiteten (målt på en skala fra 0 til 100) tre dage efter at have modtaget lægemidlet samt tiden indtil det næste anfald af urinsur gigt.
The main measures of effectiveness were pain intensity (measured on a scale from 0 to 100) 3 days after taking the medicine, as well as the time to a first new attack of gouty arthritis.
Det primære effektmål var tidsrummet, indtil sygdommen vendte tilbage eller patienten døde.
The main measure of effectiveness was the length of time until the disease came back or the patient died.
Det primære effektmål var ændringen af antallet af bogstaver, som kunne læses i en synsprøve efter 24 ugers behandling.
The main measure of effectiveness was the change in the number of letters that could be read in an eye test after 24 weeks of treatment.
Det primære effektmål var ændringen af hiv-koncentrationen i patienternes blod (den virale belastning).
The main measure of effectiveness was the change in the levels of HIV in the patients’ blood (viral load).
Det primære effektmål var ændringen i antallet af anfald efter 11 til 12 uger, til generaliseret angst blev der gennemført otte undersøgelser, som omfattede over 3 000 patienter.
The main measure of effectiveness was the change in the number of seizures after 11 to 12 weeks; for generalised anxiety disorder, there were eight studies involving over 3,000 patients.
Det primære effektmål var ændringen i knogletæthed (en målestok for, hvor stærke knoglerne er) i lændehvirvelsøjlen efter et års behandling.
The main measure of effectiveness was the change in bone density (a measure of how strong the bones are) in the lumbar (lower) spine after a year of treatment.
Det primære effektmål var ændringen i knogletætheden i lændehvirvelsøjlen efter et års behandling.
The main measure of effectiveness was the change in bone density in the lumbar spine after a year of treatment.
Det primære effektmål var ændringen i knogletætheden i lændehvirvelsøjlen efter to år.
The main measure of effectiveness was the change in bone density of the lumbar spine after two years.
Det primære effektmål var ændringen i symptomerne over 26 uger vurderet på en standardskala (UPDRS, Unified Parkinson’s Disease Rating Scale).
The main measure of effectiveness was the change in symptoms over 26 weeks, as assessed on a standard scale (Unified Parkinson’s Disease Rating Scale, UPDRS).
Det primære effektmål var, at læsionerne var fuldstændig helet 12 uger efter den sidste fotodynamiske behandling.
The primary endpoint was complete patient clearance after 12 weeks following the last photodynamic therapy.
Det primære effektmål var, hvor hurtigt patienterne opnåede smertelindring efter at have haft gennembrudssmerter.
The main measure of effectiveness was how quickly the patients had pain relief after experiencing breakthrough pain.
Det primære effektmål var, hvor lang tid der gik, inden patientens sygdom blussede op igen.
The main measure of effectiveness was how long it was before the patient’s disease flared up again.
Det primære effektmål var, hvor lang tid patienterne levede uden en forværring af sygdommen.
The main measure of effectiveness was how long the patients lived without the disease getting worse.
Det primære effektmål var, hvor lang tid patienterne overlevede.
The main measure of effectiveness was how long the patients survived.
Det primære effektmål var, hvor længe patienterne levede uden at sygdommen blev forværret.
The main measure of effectiveness was how long the patients lived without their disease getting worse.
Det primære effektmål var, hvordan Bretaris Genuair forbedrede patienternes forcerede respiratoriske volumen (FEV1, den største volumen af luft, som en person kan udånde på 1 sekund) efter seks måneder.
The main measure of effectiveness was how Bretaris Genuair improved patients’ forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after six months.
Det primære effektmål var, hvordan Eklira Genuair forbedrede patienternes forcerede respiratoriske volumen (FEV1, den største volumen af luft, som en person kan udånde på 1 sekund) efter seks måneder.
The main measure of effectiveness was how Eklira Genuair improved patients’ forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after six months.
Det primære effektmål var, i hvor lang tid patienterne var i "on"- eller ”off”- tilstand.
The main measure of effectiveness was how long the patients spent in the ‘off’ or in the ‘on’ state.
Det primære effektmål ved denne gennemgang var antallet af patienter, hvor der ikke kunne iagttages manglende terapeutisk effekt.
The main measure of effectiveness in this review was the number of patients who did not have ‘treatment failure’.
Det primære endepunkt for begge induktionsstudier var andelen af forsøgspersoner med klinisk respons (defineret som en reduktion i CDAI-score på ≥ 100 point) i uge 6.
The primary endpoint for both induction studies was the proportion of subjects in clinical response (defined as a reduction in CDAI score of ≥ 100 points) at week 6.
Det primære endepunkt for begge studier var antallet af eksemudbrud, der krævede en ’betydelig terapeutisk intervention’ i DCP, defineret som en forværring med IGA på 3-5 (dvs. moderat, alvorlig eller meget alvorlig sygdom) på den første dag med eksemudbrud, og som krævede mere end 7 dages behandling.
The primary endpoint in both studies was the number of disease exacerbations requiring a “substantial therapeutic intervention” during the DCP, defined as an exacerbation with an IGA of 3-5 (i.e. moderate, severe and very severe disease) on the first day of the flare, and requiring more than 7 days treatment.
Det primære endepunkt for begge studier var den samlede forekomst af VTE (inklusive lungeemboli, proksimal og distal DVT, hvad enten VTE var symptomatisk eller asymptomatisk (påvist ved rutine- flebografi) samt alle dødsfald uanset årsag.
Composite of total VTE (including PE, proximal and distal DVT, whatever symptomatic or asymptomatic detected by routine venography) and all-cause mortality constituted the primary end-point for both studies.
Det primære endepunkt for de 2 studier, er den 4 ugers vedvarende kvit-rate (4-week Continuous Quit Rate, 4W-CQR) fra uge 9 til og med uge 12, som er bekræftet ved måling af carbonmonoxid (CO).
The primary endpoint of the two studies was the carbon monoxide (CO) confirmed, 4 week continuous quit rate (4W-CQR) from week 9 through week 12.
Det primære endepunkt for de to forsøg med delhudstransplantat var den intraindividuelle forskel i tiden til lukning af såret (mindst 95 % epitelialisering) baseret på blindet beskrivelse af fotos.
The primary endpoint for the two split-thickness skin graft trials was the intra- individual difference in time to wound closure (at least 95% epithelialisation) based on blinded photo evaluations.
Det primære endepunkt for dette studie var progressionsfri overlevelse (PFS), baseret på studieinvestigatorernes vurdering af sygdomsprogression.
The primary endpoint of this trial was progression free survival (PFS), based on trial investigators’ assessment of disease progression.
Det primære endepunkt for effekt omfattede bekræftet symptomatisk tilbagevendende ikke fatal VTE og fatal VTE indberettet frem til dag 97.
The primary efficacy endpoint was the composite of confirmed symptomatic recurrent non-fatal VTE and fatal VTE reported up to Day 97.
Det primære endepunkt for effekt omfattede bekræftet symptomatisk tilbagevendende ikke letal VTE og letal VTE indberettet frem til dag 97.
The primary efficacy endpoint was the composite of confirmed symptomatic recurrent non-fatal VTE and fatal VTE reported up to Day 97.
Det primære endepunkt for studiet var klinisk succesrate ved opfølgning (dag 12-14) for forsøgspersoner i ’Intent to Treat’ populationen (se tabel nedenfor).
The study failed to meet the primary end point which was the clinical success rate at follow-up (day 12 – 14) for subjects in the Intent to Treat Clinical population (see Table below).
Det primære endepunkt for studiet var progressionsfri overlevelse (PFS) baseret på investigators vurdering.
The primary endpoint of the study was PFS by investigator assessment.
Det primære endepunkt for studiet var progressionsfri overlevelse (PFS) evalueret ved RECIST (Response Evaluation Criteria in Solid Tumours) baseret på investigators vurdering (lokal radiologi).
The primary endpoint for the study was progression-free survival (PFS) evaluated by RECIST (Response Evaluation Criteria in Solid Tumors), based on the investigator’s assessment (local radiology).
Det primære endepunkt for undersøgelsen var en reduktion af serumkalcium på  1 mg/dl ( 0,25 mmol/l).
The primary endpoint of the study was a reduction of serum calcium of  1 mg/dl ( 0.25 mmol/l).
Det primære endepunkt for virkning var i begge studier den absolutte ændring fra baseline i ppFEV1 ved uge 24.
The primary efficacy endpoint in both studies was the absolute change from baseline in ppFEV1 at week 24.
Det primære endepunkt i denne undersøgelse, progression-fri overlevelse (PFS), var signifikant længere i TPF-armen sammenlignet med PF-armen, p = 0,0042 (median PFS: 11,4 vs.
The primary endpoint in this study, progression-free survival (PFS), was significantly longer in the TPF arm compared to the PF arm, p = 0.0042 (median PFS: 11.4 vs.
Det primære endepunkt i denne undersøgelse, progression-fri overlevelse (PFS), var signifikant længere i TPF-armen sammenlignet med PF-armen, p = 0,0042 (median PFS: 11,4 vs.
The primary endpoint in this study, progression-free survival (PFS), was significantly longer in the TPF arm compared to the PF arm, p=0.0042 (median PFS: 11.4 vs.
Det primære endepunkt i dette studie, progression-fri overlevelse (PFS), var signifikant længere i TPF-armen sammenlignet med PF-armen, p = 0,0042 (median PFS: 11,4 vs.
The primary endpoint in this study, progression-free survival (PFS), was significantly longer in the TPF arm compared to the PF arm, p = 0.0042 (median PFS: 11.4 vs.
Det primære endepunkt i RA-studie I, II og III og det sekundære endepunkt i RA-studie IV var den procentdel af patienter, som fik ACR 20-respons i uge 24 eller 26.
The primary end point in RA studies I, II and III and the secondary endpoint in RA study IV was the percentage of patients who achieved an ACR 20 response at Week 24 or 26.
Det primære endepunkt i RA-studie V var procentdelen af patienter, som opnåede et -50 respons i uge 52.
The primary endpoint in RA study V was the percent of patients who achieved an ACR 50 response at Week 52.
Det primære endepunkt i SMART var det kombinerede antal luftvejsrelaterede dødsfald og luftvejsrelaterede livstruende hændelser.
The primary endpoint in SMART was the combined number of respiratory-related deaths and respiratory-related life-threatening experiences.
Det primære endepunkt i studiet var samlet overlevelse.
The primary endpoint of the study was overall survival.
Det primære endepunkt i studiet var skeletal morbidity period rate (SMPR).
The primary endpoint of the trials was the skeletal morbidity period rate (SMPR).
Det primære endepunkt og andre resultater fra uge 48 (herunder resultater fra nøgle-baseline-kovariater) i SPRING-2 og SINGLE er vist i tabel 3.
The primary endpoint and other week 48 outcomes (including outcomes by key baseline covariates) for SPRING-2 and SINGLE are shown in Table 3.
Det primære endepunkt var andelen af patienter, der oplevede en klinisk effekt, bestemt som en nedgang i CDAI på ≥ 70 point fra baseline ved 4-ugers evalueringen og uden stigning i brugen af lægemidler eller kirurgiske indgreb for Crohns sygdom.
The primary endpoint was the proportion of patients who experienced a clinical response, defined as a decrease in CDAI by ≥ 70 points from baseline at the 4-week evaluation and without an increase in the use of medicinal products or surgery for Crohn’s disease.
Det primære endepunkt var andelen af patienter, der oplevede en klinisk effekt, bestemt som ≥ 50 % reduktion fra basislinien i antallet af fistler, drænet ved forsigtigt tryk, ved mindst to på hinanden følgende besøg (med 4 ugers mellemrum) uden øget brug af lægemidler eller kirurgisk indgreb for Crohns sygdom.
The primary endpoint was the proportion of patients who experienced a clinical response, defined as ≥ 50% reduction from baseline in the number of fistulae draining upon gentle compression on at least two consecutive visits (4 weeks apart), without an increase in the use of medicinal products or surgery for Crohn’s disease.
Det primære endepunkt var andelen af patienter, der oplevede en klinisk virkning, bestemt som en nedgang i CDAI på ≥ 70 point fra baseline ved 4-ugers evalueringen og uden stigning i brugen af lægemidler eller kirurgiske indgreb for Crohns sygdom.
The primary endpoint was the proportion of patients who experienced a clinical response, defined as a decrease in CDAI by ≥70 points from baseline at the 4-week evaluation and without an increase in the use of medicinal products or surgery for Crohn’s disease.
Det primære endepunkt var andelen af patienter, der oplevede en klinisk virkning, bestemt som en nedgang i CDAI på ≥ 70 point fra baseline ved 4-ugers evalueringen og uden stigning i brugen af lægemidler eller kirurgiske indgreb for Crohns sygdom.
The primary endpoint was the proportion of patients who experienced a clinical response, defined as ≥50% reduction from baseline in the number of fistulae draining upon gentle compression on at least two consecutive visits (4 weeks apart), without an increase in the use of medicinal products or surgery for Crohn’s disease.
Det primære endepunkt var andelen af patienter, der oplevede en klinisk virkning, bestemt som ≥ 50 % reduktion fra baseline i antallet af fistler, drænet ved forsigtigt tryk, ved mindst to på hinanden følgende besøg (med 4 ugers mellemrum) uden øget brug af lægemidler eller kirurgisk indgreb for Crohns sygdom.
The primary endpoint was the proportion of patients who experienced a clinical response, defined as ≥50% reduction from baseline in the number of fistulae draining upon gentle compression on at least two consecutive visits (4 weeks apart), without an increase in the use of medicinal products or surgery for Crohn’s disease.
Det primære endepunkt var andelen af patienter, der opnåede ASAS 20- respons ved uge 16.
In GO-AFTER, the primary endpoint was the percentage of patients achieving an ACR 20 response at week 14.
Det primære endepunkt var andelen af patienter, der opnåede ASAS 20- respons ved uge 16.
The primary endpoint was the proportion of patients achieving ASAS 20 response at week 16.
Det primære endepunkt var andelen af patienter, der opnåede HbA1c < 7 % uden bekræftet eller alvorlig hypoglykæmi.
Primary endpoint was the proportion of patients reaching HbA1c <7% without confirmed or severe hypoglycaemia.